Rain Therapeutics Inc. (RAIN) News
Filter RAIN News Items
RAIN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RAIN News Highlights
- For RAIN, its 30 day story count is now at 4.
- Over the past 14 days, the trend for RAIN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RARE are the most mentioned tickers in articles about RAIN.
Latest RAIN News From Around the Web
Below are the latest news stories about RAIN ONCOLOGY INC that investors may wish to consider to help them evaluate RAIN as an investment opportunity.
Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual CongressNEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an abstract accepted as a proffered paper presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland. Presentation Title:MDM2 inhibitor milademetan: safety profi |
Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call TranscriptRain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of Live Site Advisors. Thank you. You may […] |
Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Topline data for Phase 3 pivotal MANTRA trial expected in second quarter of 2023 – – Phase 2 MANTRA-2 trial continues to enroll – – Phase 1/2 MANTRA-4 trial anticipated to commence in mid-2023 – – Management to host conference call and webcast |
Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare ConferenceNEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in |
Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023. On that day, management will |
TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 StocksJanuary saw the markets start off the new year with strong gains, while February has seen them level off. In the last two weeks, the main indexes have seen range-bound trading; investor sentiment remains upbeat for now, but there is some doubt about where stocks are headed longer-term. It is an environment that makes it hard to find the potential winners. What’s needed is a tool to cut through the uncertainty. The Smart Score tool, at TipRanks, is designed to do just that. At base, the tools col |
Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership SummitNEWARK, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Citi Virtual Oncology Leadership Summit on Tuesday, February 21, 2023, at 12:00 p.m. ET, bein |
UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day ConferenceNEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9, 2023, at 3:55 p.m. ET. Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Ch |
Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day ConferenceNEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on Wednesday, February 8, 2023, at 9:35 a |
Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRA trial – NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, mi |